Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 3
2009 13
2010 16
2011 32
2012 28
2013 37
2014 36
2015 52
2016 48
2017 62
2018 53
2019 50
2020 63
2021 51
2022 72
2023 72
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

670 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Early Stage Triple-Negative Breast Carcinoma"
Page 1
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Masuda N, et al. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. N Engl J Med. 2017. PMID: 28564564 Free article. Clinical Trial.
BACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. ...Overall survival was longer in the capecitabine group th …
BACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth fa …
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Bianchini G, et al. Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17. Nat Rev Clin Oncol. 2016. PMID: 27184417 Free PMC article. Review.
Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of targeted therapies and the poor prognosis of patients with …
Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in bo …
Updates on breast biomarkers.
Najjar S, Allison KH. Najjar S, et al. Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35029776 Review.
These advancements have shifted the pathologist's practice into a leading role in the management breast cancer. Understanding the complex algorithms and diagnostic modalities used to assess predictive and prognostic biomarkers is central for quality oncology …
These advancements have shifted the pathologist's practice into a leading role in the management breast cancer. Understanding the com …
Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D. Kwapisz D. Cancer Immunol Immunother. 2021 Mar;70(3):607-617. doi: 10.1007/s00262-020-02736-z. Epub 2020 Oct 5. Cancer Immunol Immunother. 2021. PMID: 33015734 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone (PgR) receptors as well as human epidermal growth factor receptor 2 (HER2) and is associated with poor prognosis. ...Recently, pembrolizumab …
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone (PgR) re …
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5. Future Oncol. 2022. PMID: 35378995 Review.
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast cancer. ...Herein we will provide an overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients …
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early …
Treatment of Breast Cancer in Young Adults.
Tesch ME, Partridge AH. Tesch ME, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_360970. Am Soc Clin Oncol Educ Book. 2022. PMID: 35580291 Free article.
Given breast cancers arising at a young age are more likely to present at advanced stages and to have aggressive biology, multimodal treatments are often indicated. ...Recently, escalated systemic therapy regimens for triple-negative breast canc …
Given breast cancers arising at a young age are more likely to present at advanced stages and to have aggressive biology, mult …
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4. Cancer Cell. 2023. PMID: 37146605 Free PMC article.
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personal …
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden as …
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Leon-Ferre RA, et al. JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056. JAMA. 2024. PMID: 38563834
IMPORTANCE: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or n …
IMPORTANCE: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death …
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
IMPORTANCE: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. ...Patients (n = 443) had early-stage triple-negative breast …
IMPORTANCE: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rat …
Immunotherapy Approaches for Breast Cancer Patients in 2023.
Emens LA, Loi S. Emens LA, et al. Cold Spring Harb Perspect Med. 2023 Apr 3;13(4):a041332. doi: 10.1101/cshperspect.a041332. Cold Spring Harb Perspect Med. 2023. PMID: 37011999 Review.
The PD-1 inhibitor pembrolizumab combined with neoadjuvant chemotherapy followed by adjuvant pembrolizumab improves event-free survival and is a new standard of care for high-risk, early-stage triple-negative breast cancer (TNBC), regardless of …
The PD-1 inhibitor pembrolizumab combined with neoadjuvant chemotherapy followed by adjuvant pembrolizumab improves event-free survival and …
670 results